Grant of PDMR Options

15 March 2022

Instem plc
("Instem" or the "Company")

Grant of PDMR Options

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that Phil Reason (Chief Executive Officer) and Nigel Goldsmith (Chief Financial Officer) have each been granted awards of nil-cost options over 4,833 and 2,165 Ordinary Shares respectively under the Instem plc 2018 Long Term Incentive Plan ("LTIP").  These options will ordinarily vest and become exercisable on 1 January 2025 pursuant to the rules of the LTIP.

After these grants of options, Mr Reason and Mr Goldsmith hold options over a total of 133,649 and 261,696 Ordinary Shares, respectively.  

For further information, please contact:

Instem plc Via Walbrook
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel  
Alex Bond  
Rachel Hayes  
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0)20 7710 7600
Ben Maddison  
Alex Price  
Wallbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper
Nick Rome  

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit